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The immunosuppressive effects of FR 900506 were studied 
in Lewis rats given ACI heterotopic heart allografts. 
Intramuscular doses of 0.02 mg/kg daily for 2 weeks extended 
graft survival slightly, and with doses up to 1.28 mg/kg for 
·2 weeks, there is long-term graft survival. If only 3 daily 
doses were given starting on day 4 after transplantation, 
graft survival for almost 3 months was accomplished in 4 of 
. 6 animals who still bear functioning hearts. 
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FR 900506 (FR) is a new irrnnunosuppressive agent 
with a molecular weight of 822.05 Daltons which was 
isolated from Streptomyces tsukubaensis in Japan (1). 
By in Y.i1ro testing it inhibits interleukin 2 (lL-2) 
production, inhibits mixed mouse lymphocyte culture 
cellular reactions, stops the generation of mouse 
cytotoxic T cells, and inhibits the appearance of IL-2 
recep tor s on human lymphocytes. These ef f ec t s of FR 
are about 500 to 1000 times more potent than those of 
cyclosporin A (CsA). 
Pilot in YiYQ studies (1) have shown that FR can 
prolong the survival time of skin and heterotopic 
cardiac allografts in rats and renal allografts in 
dogs. We report here studies in rats on the optimal 
dosage of FR, the timing of drug administration, and 
the effectiveness of FR in reversing ongoing rejection. 
Animals 
Inbred male rats were used in all experiments. 
Lewis rats (RT 11) weighing 200 - 250 gm. were used as 
recipients. ACI rats (RT 1a ) weighing 150 - 200 gm. 
were used as hear t donor s • Lewis rats were purchased 
from the Harlian Sprague Dawley (Indianapolis, 
Indiana), and ACI rats were purchased from the Simonsen 
Lab. (Gilcoy, California). 
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Operative Procedures 
Heterotopic cardiac transplantation was performed 
by anastomosis of the donor aorta and pulmonary artery 
to the recipient aorta and infrarenal inferior vena 
cava wi th standard microvascular techniques (2). 
Impulses of the transplanted heart grafts were palpated 
daily through the abdominal wall of the recipients. 
Rejection was diagnosed by the cessation of heart beat 
and confirmed visually by laparotomy and histological 
examination. Of the 78 recipient rats treated with FR, 
3 died with living grafts and were excluded from 
stat i s tic a I a n a I y sis. All animal s are accounted for 
individually in Tables 1-3. 
Drug Administration 
FR for intramuscular use was kindly suppl ied by 
Fujisawa Pharmaceutical Co., Osaka, Japan, as a 
crystalline powder. It was dissolved in saline and was 
injected in the thigh once a day. 
Experim ental Designs 
Recipient rats were divided into seventeen groups. 
Another seven recipient rats without immunosuppressive 
treatment were used as control group. 
~ response studies --- For ty-two rec i pi en t ra t s 
were divided into seven groups of 6 to test the 
e f f e c t i v en e s s 0 f FR i n do s e s from o. 0 2 mg / kg / day for 
two weeks to 1.28 mg/kg/day for two weeks (Table 1). 
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Treatment timing studies --- The best dose from the 
above experiments was judged to be 1.28 mg/kg/day. 
Using this daily dose, 6 groups of animals were treated 
at various time intervals before transplantation (Table 
2). Another 4 groups were treated at different times 
aft e r t ran s p I ant a t ion (Ta b I e 3). From 0 net 0 4 do s e s 
were given (Tables 2 and 3). 
Statistical Analysis 
Graft survival times were compared using Wilcoxon 
rank sum test. 
Dose repfOnns~ studies --- All allografted hearts 
without FR treatment were rejected within 7 days 
(median survival time 6 days) (Table 1). All of the 
cardiac allograft survival times were significantly 
prolonged with two weeks treatment starting on the day 
of operation, compared with the control group (Table 
1). Daily doses as small as 0.02 mg/kg and 0.04 mg/kg 
had a slight but significant effect (Table 1). Between 
doses of 0.08 mg/kg and 0.64 mg/kg for 2 weeks, the 
median survival times were between 32 and 39 days. At 
I.M. doses of 1.28 mg/kg/day for two weeks, the 
survival times were remarkably prolonged (median 
survival time 87 days) • 
.Il:ruilment timi~ studies --- The opt imum dose of 1.28 
mg/kg was used. I.M. single dose treatment before 
operation was ineffective (Table 2). However, 2 to 4 
doses on the days before grafting increased greatly the 
graft survival times (Table 2). 
IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 329 
Therapy with 1.28 mg/kg/day after transplantation 
was even more effective (Table 3). Two or 3 daily 
doses just after operation prolonged survival to more 
than a month. The most striking results were when 
treatment was delayed to the fourth postoperative day. 
Then, a remarkable "rescue" was evident, and 4 animals 
from this group of 6 are approaching 3 months survival 
(Table 3). 
IUSg]SSlOO 
In confirmation of the original work of Ochiai et 
al (1), the potency of FR 900506 was evident in this 
study. The dose range of demonstrable effect was very 
broad, from .02 to 1.28 mg/kg/day without a toxicity-
imposed ceiling being reached. Furthermore, there was 
no obvious histopathologic or clinical evidence of drug 
toxicity, even at the highest I.M. dose (unpublished 
observations). 
Sop 0 ten tis FR 9 0 0 5 0 6 t hat 2, 3, 0 r 4 do s e s 0 f 
1.28 mg/kg given I.M. before transplantation permitted 
prolonged survival without postoperative treatment. 
The most remarkable observation was that 3 daily doses 
started after 4 days, almost on the eve of anticipated 
rejection, allowed almost unlimited subsequent graft 
survival in 4 of 6 recipients. This ability to rescue 
heterotopic heart grafts from rejection was far greater 
than that reported for cyclosporine (3). 
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TABLE 1 
bcc~ OF FR 900506 IN VAHOUS DOSES UPON THE GRAFT SURVIVAL 
OF LEWIS RATS RI«:E:VING AO HEARl' 
1'ree.tment Btt No. Qooft Survival 
(Dlys) 
Control 7 
0.02 mg/kg I.M. roily 6 
for 14 wys 
0.04 mg/kg I.M. wily 6 
for 14 days 
0.08 mg/kg I.M. wily 6 
for 14 days 
0.16 mg/kg I.M. wily 6 
for 14 wys 
0.32 mg/kg I.M. wily 6 
for 14 days 
0.64 mg/kg I.M. wily 6 
for 14 days 
1.28 mg/kg I.M. wily 6 
for 14 wys 
@ ~ with control grwp 
* Died with living graft 
6, 6, 6, 6, 7, 7, 
7 
7, 7, 8, 8, 9, 
9 
9, 10, 10, 11, 24, 
34 
12, 14, 32, 36, 
40, 10* 
27, 30, 32, 33, 
55, 14* 
27, 30, 37, 39, 
39, 49 
33, 34, 36, 42, 
43, 84 
56, 71, 80, 94, 
96, >150 
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TABLE 2 
FR 900506 GIVEN I.M. BEFORE TRANSPLANTA110N: 
GRAFT SURVIVAL OF LEWIS RATS ROCFlVING AO HEARTS 
T.rultment Bit No. 
1.28 mg/kg once 3 
on my -4 
1.28 mg/kg once 3 
on my -2 
1.28 mg/kg once 3 
on my -1 
1.28 mg/kg on 3 
mys -2, -1 
1.28 mg/kg on 3 
mys -3, -2, -1 
1.28 mg/kg I.M. 6 
mily on days 
-4, -3, -2, -1 
* Died with living graft 
Graft &lrvival 
(Days) 
6, 6, 6 
8, 8, 8 
7, 8, 9 
18, 30, 37 
33, 35, 48 










FR 900506 GIVEN I.M. AFTER TRANSPLANTA110N: 
GRAFT SURVIVAL OF LEWIS RATS RECHVING AO HEARTS 
T.rultment 
1.28 mg/kg on 
mys 0, 1 
1.28 mg/kg on 
mys 2, 3 
1.28 mg/kg on 
ffiys 0, 1, 2 
1.28 mg/kg on 
mys 4, 5, 6 
Bit No. Graft &lrvival 
(nIys) 
3 22, 31, 53 
3 30, 49, >48 
3 23, 35, 36 
6 23, 51, >84, 
>87, >87, >87 
Median (Days) 
31 
49 
35 
>87 
